Reassortant Or Deletion Mutant Virus Patents (Class 424/205.1)
-
Patent number: 8691239Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: September 25, 2013Date of Patent: April 8, 2014Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8679509Abstract: The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.Type: GrantFiled: July 9, 2010Date of Patent: March 25, 2014Assignee: The Governors of the University of AlbertaInventors: David H. Evans, Don B. Gammon
-
Patent number: 8673315Abstract: The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.Type: GrantFiled: November 26, 2008Date of Patent: March 18, 2014Assignee: London School of Hygiene & Tropical MedicineInventors: Polly Roy, Mark Boyce
-
Patent number: 8663653Abstract: The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analysis.Type: GrantFiled: July 24, 2009Date of Patent: March 4, 2014Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Maria Lisa Knudsen, Troels Kasper Høyer Scheel, Jens Bukh
-
Patent number: 8658610Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.Type: GrantFiled: September 16, 2009Date of Patent: February 25, 2014Assignee: Saint Louis UniversityInventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
-
Publication number: 20140050761Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.Type: ApplicationFiled: March 14, 2013Publication date: February 20, 2014Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
-
Publication number: 20140030290Abstract: An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines.Type: ApplicationFiled: September 30, 2013Publication date: January 30, 2014Applicant: Boehringer Ingelheim Vetmedica GmbHInventors: Johanna Jacoba Maria Meulenberg, Johannes Maria Antonius Pol, Judy Norma Aletta Bos-de Ruijter
-
Publication number: 20140023679Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: October 2, 2012Publication date: January 23, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20140017313Abstract: This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.Type: ApplicationFiled: July 5, 2013Publication date: January 16, 2014Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Mónica Rosa
-
Patent number: 8623381Abstract: The present invention relates to viral strains derived from the vaccinia virus Lister VACV-107 and to pharmaceutical composition containing the viral strains. More particularly, the present invention relates to a viral strain derived from the vaccinia virus Lister VACV-107 wherein strain contains in its genomic sequence (SEQ ID N°1) at least one deletion selected from the group consisting of: deletion of the nucleotides 19758 to 28309 in the sequence ID NO°1 (?18), deletion of the nucleotides 161293 to 164811 in the sequence ID NO°1 (?20), deletion of the nucleotides 181231 to 183304 in the sequence ID NO°1 (?21), deletion of the nucleotides 6118 to 9677 in the sequence ID NO°1 (?22), deletion of the nucleotides 1833 to 3574 and 185848 to 187589 in the sequence ID NO°1 (?23).Type: GrantFiled: September 18, 2009Date of Patent: January 7, 2014Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Jean-marc Crance, Daniel Garin, Daniele Gratier, Anne-Laure Favier, Robert Drillien, Matthias Hebben, Daniele Spehner, Karine Pradeau
-
Publication number: 20140004147Abstract: Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5? non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3? NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3? NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240.Type: ApplicationFiled: August 30, 2013Publication date: January 2, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Alexander G. Pletnev, Brian R. Murphy, Amber R. Engel
-
Patent number: 8604179Abstract: This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5? to 3? direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.Type: GrantFiled: April 24, 2009Date of Patent: December 10, 2013Assignees: Toray Industries, Inc., Japan As Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Organization for Medical ResearchInventors: Daisuke Akazawa, Takaji Wakita
-
Publication number: 20130323278Abstract: A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.Type: ApplicationFiled: December 3, 2012Publication date: December 5, 2013Inventor: Thomas J. CHAMBERS
-
Patent number: 8597661Abstract: Attenuated, neuraminidase deficient influenza virus, and compositions and methods to prepare that virus, are provided.Type: GrantFiled: May 1, 2008Date of Patent: December 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Masato Hatta
-
Patent number: 8580277Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: March 31, 2011Date of Patent: November 12, 2013Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Kanta Subbaro, Brian Murphy
-
Patent number: 8574593Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: December 7, 2012Date of Patent: November 5, 2013Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8574591Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.Type: GrantFiled: November 15, 2011Date of Patent: November 5, 2013Assignee: Medimmune, LLCInventors: Erich Hoffmann, Hong Jin, George Kemble, Zhongying Chen
-
Patent number: 8574592Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.Type: GrantFiled: September 13, 2012Date of Patent: November 5, 2013Assignee: St. Jude Children's Research HospitalInventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
-
Patent number: 8568739Abstract: Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5? non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3? NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3? NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240.Type: GrantFiled: May 28, 2010Date of Patent: October 29, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alexander G. Pletnev, Brian R. Murphy, Amber R. Engel
-
Publication number: 20130251747Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicants: FREIE UNIVERSITÄT BERLIN, MERIAL LIMITEDInventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Patent number: 8524247Abstract: Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.Type: GrantFiled: August 20, 2009Date of Patent: September 3, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Xianfu Wu, Charles Rupprecht
-
Publication number: 20130224235Abstract: A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein and DNA vaccines, based on potato virus A coat protein.Type: ApplicationFiled: October 19, 2009Publication date: August 29, 2013Applicants: University of Tartu, Tallinn University of TechnologyInventors: Lilian Järvekülg, Viiu Paalme, Ülo Puurand, Sirje Rüütel Boudinot, Sulev Kuuse, Reet Rumvolt, Ave Laas
-
Publication number: 20130224144Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: ApplicationFiled: September 18, 2012Publication date: August 29, 2013Applicant: Etubics CorporationInventors: Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
-
Publication number: 20130224243Abstract: Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator.Type: ApplicationFiled: February 15, 2013Publication date: August 29, 2013Inventors: Samuel D. Rabkin, Masahiro Toda, Robert L. Martuza
-
Patent number: 8506969Abstract: Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.Type: GrantFiled: July 31, 2009Date of Patent: August 13, 2013Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
-
Patent number: 8506967Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: December 19, 2008Date of Patent: August 13, 2013Assignee: Novavax, Inc.Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
-
Publication number: 20130195914Abstract: The invention relates to the fields of viruses, vaccines and compounds and methods for expression. In particular, the invention includes methods and agents capable of producing quantities of a vaccine to a positive sense single stranded RNA (“(+)sense RNA”)virus.Type: ApplicationFiled: April 8, 2011Publication date: August 1, 2013Applicant: Viracine Therapeutics CorporationInventor: Arun K. Dhar
-
Patent number: 8486419Abstract: Disclosed is an attenuated flavivirus live vaccine comprising a flavivirus mutant, characterized in that the flavivirus mutant has a deletion in the capsid protein of at least more than 4 successive amino acids, wherein the carboxy-terminal hydrophobic region is not affected by the deletion.Type: GrantFiled: February 11, 2002Date of Patent: July 16, 2013Assignee: Intercell AGInventors: Franz Xaver Heinz, Christian Mandl
-
Patent number: 8481050Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.Type: GrantFiled: August 22, 2007Date of Patent: July 9, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
-
Patent number: 8475806Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes a sequence from a high titer influenza virus isolate.Type: GrantFiled: May 27, 2004Date of Patent: July 2, 2013Assignee: Wisconsin Alumni Research FoundationInventor: Yoshihiro Kawaoka
-
Patent number: 8470577Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.Type: GrantFiled: March 11, 2010Date of Patent: June 25, 2013Assignees: Catherex, Inc., The General Hospital Corporation, Georgetown UniversityInventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
-
Patent number: 8465960Abstract: An isolated influenza B virus which has reduced sensitivity to one or more neuraminidase (NA) inhibitors, wherein the reduced sensitivity to one or more NA inhibitors is associated with a residue in NA other than Ile at position 222, a residue in NA other than Ser at a position 250, or a residue in NA other than Gly at position 402, as well as methods to detect such a virus or determine agents that inhibit the infection or replication of such as virus, are provided.Type: GrantFiled: March 28, 2008Date of Patent: June 18, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Shuji Hatakeyama
-
Publication number: 20130142824Abstract: The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques.Type: ApplicationFiled: June 2, 2011Publication date: June 6, 2013Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.Inventors: Yanyan Ni, Yao-Wei Huang, Xiang-Jin Meng
-
Publication number: 20130129780Abstract: Provided herein are modified infectious largotracheitis viruses (ILTVs) and methods of using the same. For example, provided are attenuated ILTVs. The attenuated ILTVs can be used to illicit immune responses in avian species. Optionally, the attenuated ILTVs can be used to vaccinate an avian subject or a population of avian subjects. Optionally, an attenuated ILTV is administered in ovo to an avian egg. One or more such in ovo administration can be used to increase the immunity of an avian herd.Type: ApplicationFiled: August 2, 2011Publication date: May 23, 2013Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: Maricarmen Garcia, Alice Mundt, Egbert Mundt
-
Publication number: 20130115244Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: October 1, 2012Publication date: May 9, 2013Applicant: Yisheng Biopharma (Singapore) PTE. LTD.Inventor: Yisheng Biopharma (Singapore) PTE. LTD.
-
Patent number: 8431137Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: September 12, 2011Date of Patent: April 30, 2013Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20130071432Abstract: One aspect of the present disclosure relates to a method for treating a subject with cancer. The method includes administering an oncolytic virus simultaneously, sequentially, or separately in combination with an immunomodulatory agent in an amount effective to suppress both antiviral immunity and angiogenesis associated with the cancer.Type: ApplicationFiled: September 18, 2012Publication date: March 21, 2013Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Robert Silverman, Babal Kant Jha
-
Patent number: 8394385Abstract: The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.Type: GrantFiled: March 9, 2010Date of Patent: March 12, 2013Assignee: Bavarian Nordic A/SInventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann
-
Publication number: 20130034585Abstract: A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5?30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 UL49.5?30-32 CT-null/gE CT?/Us9? virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.Type: ApplicationFiled: December 14, 2011Publication date: February 7, 2013Inventors: SHAFIQUL I. CHOWDHURY, HUI YONG WEI
-
Patent number: 8354114Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics.Type: GrantFiled: October 17, 2006Date of Patent: January 15, 2013Assignee: Medimmune, LLCInventors: Bin Lu, Hong Jin
-
Publication number: 20120328652Abstract: The invention is in the field of virus vaccines for protecting animals against infection by parvovirus, their production and use. More in particular, the invention is related to a vaccine comprising an attenuated parvovirus comprising a capsid protein or fragment thereof derivable from another parvovirus. Surprisingly it was found that such a vaccine was capable of inducing higher titers of protecting antibodies against a challenge with the second type of parvovirus strains while maintaining good immunity against the first type of parvovirus. Recombinant virus strains also remained attenuated.Type: ApplicationFiled: March 3, 2011Publication date: December 27, 2012Inventor: Norman Spibey
-
Patent number: 8333975Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: December 16, 2011Date of Patent: December 18, 2012Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20120315295Abstract: We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.Type: ApplicationFiled: June 9, 2011Publication date: December 13, 2012Inventors: Aida E. Rieder, Luis L. Rodriguez, Jason R. Hollister, Sabena Uddowla
-
Patent number: 8313750Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.Type: GrantFiled: February 24, 2011Date of Patent: November 20, 2012Assignee: National Chung Hsing UniversityInventors: Chuan-Mu Chen, Hsiao-Ling Chen
-
Patent number: 8298549Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: January 4, 2010Date of Patent: October 30, 2012Assignee: Etubics CorporationInventors: Joseph P. Balint, Frank R. Jones, Richard B. Gayle, III
-
Patent number: 8293247Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.Type: GrantFiled: December 9, 2010Date of Patent: October 23, 2012Assignee: St. Jude Children's Research HospitalInventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
-
Patent number: 8252574Abstract: The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.Type: GrantFiled: February 27, 2007Date of Patent: August 28, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Peter W. Mason, Elena Frolova, Ilya Frolov
-
Publication number: 20120201850Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.Type: ApplicationFiled: February 1, 2012Publication date: August 9, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Knut Elbers, Christiane Meyer, Martina von Freyburg, Gregor Meyers
-
Publication number: 20120195927Abstract: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements.Type: ApplicationFiled: April 13, 2012Publication date: August 2, 2012Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Antonie NEUBAUER, Christina ZIEGLER
-
Publication number: 20120183574Abstract: The invention concerns the use of a virus for the preparation of a medicament for the vaccination or treatment of a human, wherein the virus is capable of infecting the cells of the human, but not capable of being replicated to infectious progeny virus in the human. The virus is preferably a Modified Vaccinia Virus Ankara.Type: ApplicationFiled: March 16, 2012Publication date: July 19, 2012Applicant: BAVARIAN NORDIC A/SInventor: Paul Chaplin